

**In the claims:**

1.-6. (canceled)

7. (Currently amended) A drug comprising a 2-imidazolyl disulfide and a pharmaceutically acceptable carrier for intravenous administration injection, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in reducing or eliminating thioredoxin-associated apoptosis inhibition.

8. (Currently amended) A drug comprising a 2-imidazolyl disulfide and a pharmaceutically acceptable carrier, for intravenous administration injection said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in inhibiting thioredoxin stimulated cell growth.

9. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

10. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

11. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits tumor growth.

12. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits tumor growth.

13. (Currently amended) The drug of claim 7 9, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

14. (Currently amended) The drug of claim 8 10, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

15. (Currently amended) The drug of claim 7 9, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

16. (Currently amended) The drug of claim 8 10 wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.
17. (Currently amended) The drug of claim 7 9, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.
18. (Currently amended) The drug of claim 8 10, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.
19. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier for oral administration, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in reducing or eliminating thioredoxin-associated apoptosis inhibition.
20. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier, for oral administration, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in inhibiting thioredoxin stimulated cell growth.
21. (Previously presented) The drug of claim 19, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
22. (Previously presented) The drug of claim 20, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
23. (Previously presented) The drug of claim 19, wherein said 2-imidazolyl disulfide inhibits tumor growth.
24. (Previously presented) The drug of claim 20, wherein said 2-imidazolyl disulfide inhibits tumor growth.
25. (Currently amended) The drug of claim 19 21, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

26. (Currently amended) The drug of claim ~~20~~ 22, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

27. (Currently amended) The drug of claim ~~19~~ 21, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

28. (Currently amended) The drug of claim ~~20~~ 22, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

29. (Currently amended) The drug of claim ~~19~~ 21, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.

30. (Currently amended) The drug of claim ~~20~~ 22, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.

31. (New) The drug of claim 9, comprising 15-45 mg/m<sup>2</sup> of 1-methylpropyl-2-imidazolyl disulfide.

32. (New) The drug of claim 10, comprising 15-45 mg/m<sup>2</sup> of 1-methylpropyl-2-imidazolyl disulfide.

33. (New) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 15mg/ m<sup>2</sup>.

34. (New) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 15 mg/m<sup>2</sup>.

35. (New) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 30 mg/m<sup>2</sup>.

36. (New) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 30 mg/m<sup>2</sup>.

37. (New) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 45 mg/m<sup>2</sup>.
38. (New) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 45 mg/m<sup>2</sup>.
39. (New) The drug of claim 21, wherein said 1-methylpropyl-2-imidazolyl disulfide is administered orally up to 250 mg/kg.
40. (New) The drug of claim 22, wherein said 1-methylpropyl-2-imidazolyl disulfide is administered orally up to 250 mg/kg.